Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Toronto

$87,680.00

Screening of Active Ingredients for Skin Care in a Microfluidic Skin Organoid Platform_x000d_

EF 2020-21

Résumé
Development of formulations for skin care products is a labor- and cost-intensive task, largely due to a large number of active ingredients (AIs) and their combinations that have to be tested on skin tissue to make a high-performance product. This time-consuming multistep process begins from the identification of a promising AI candidate and continues to optimization of a multicomponent formulation using animal models. Experiments on animal models are expensive, time-consuming, and require special skills. Furthermore, due to the ethical considerations, in 2009 animal models for cosmetic ingredients were banned by the European Union and in 2019, the Senate in Canada approved the S-214 of the Cruelty Free Cosmetics Act that prohibits the sale of cosmetics tested on animals. The utilization of in vitro skin models, e.g., multicellular organoids, organotypic micrometer-size 3D cell aggregates that replicate many features of tissues and organs, is highly recommended and favored. Currently, skin organoid models have at least, one of the following limitations: (i) broad distribution of organoid dimensions (leading to uncertainty in AI screening); (ii) poorly controlled environments for organoid growth; (iii) slow growth; and (iv) the lack of high-throughput AI screening. The objective of the proposed collaborative research is to design and develop a skin organoid-on-a-chip microfluidic platform to grow massive arrays of heterogeneous skin organoids (SOs) and utilize this MF platform for high-throughput screening of multiple AIs for skin care. Massive arrays of SOs will be grown from fibroblasts and keratinocytes, and exposed to Retinol (Vitamin A) and Vitamin C, and their mixtures, acting as representative AIs. The development of the MF platform for high-throughput screening of AIs is a vital step toward cost- and energy-effective manufacturing in the pharmaceutical, cosmetic, and skin care fields. These industrial sectors are of strategic importance in Canada and are represented by 11 production and R&D facilities of our industrial partner (BASF) in Canada. The proposed MF technology platform offers an approach to the development and optimization of AIs, thus contributing to the time-, labor- and cost-effective exploration and development of products with enhanced performance. It will enable the expansion of new technologies, thereby enhancing their potential for licensing and other commercial activities.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
556208-2020
Name nom
Kumacheva, Eugenia
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
87680
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Screening of Active Ingredients for Skin Care in a Microfluidic Skin Organoid Platform_x000d_
Keyword
NSERC
Application summary
Development of formulations for skin care products is a labor- and cost-intensive task, largely due to a large number of active ingredients (AIs) and their combinations that have to be tested on skin tissue to make a high-performance product. This time-consuming multistep process begins from the identification of a promising AI candidate and continues to optimization of a multicomponent formulation using animal models. Experiments on animal models are expensive, time-consuming, and require special skills. Furthermore, due to the ethical considerations, in 2009 animal models for cosmetic ingredients were banned by the European Union and in 2019, the Senate in Canada approved the S-214 of the Cruelty Free Cosmetics Act that prohibits the sale of cosmetics tested on animals. The utilization of in vitro skin models, e.g., multicellular organoids, organotypic micrometer-size 3D cell aggregates that replicate many features of tissues and organs, is highly recommended and favored. Currently, skin organoid models have at least, one of the following limitations: (i) broad distribution of organoid dimensions (leading to uncertainty in AI screening); (ii) poorly controlled environments for organoid growth; (iii) slow growth; and (iv) the lack of high-throughput AI screening. The objective of the proposed collaborative research is to design and develop a skin organoid-on-a-chip microfluidic platform to grow massive arrays of heterogeneous skin organoids (SOs) and utilize this MF platform for high-throughput screening of multiple AIs for skin care. Massive arrays of SOs will be grown from fibroblasts and keratinocytes, and exposed to Retinol (Vitamin A) and Vitamin C, and their mixtures, acting as representative AIs. The development of the MF platform for high-throughput screening of AIs is a vital step toward cost- and energy-effective manufacturing in the pharmaceutical, cosmetic, and skin care fields. These industrial sectors are of strategic importance in Canada and are represented by 11 production and R&D facilities of our industrial partner (BASF) in Canada. The proposed MF technology platform offers an approach to the development and optimization of AIs, thus contributing to the time-, labor- and cost-effective exploration and development of products with enhanced performance. It will enable the expansion of new technologies, thereby enhancing their potential for licensing and other commercial activities.